Cholesterol and coronary heart disease: The 21st century

Archives of Internal Medicine

Volumn 157, Issue 11, 1997, Pages 1177-1184

  Grundy, Scott M ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; DISEASE ASSOCIATION; HEALTH CARE PLANNING; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION;

EID: 0030915254     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.157.11.1177     Document Type: Article

References (70)

1. Sempos C, Cooper R, Kovar MG, McMillen M. Divergence of the recent trends in coronary mortality for the four major race-sex groups in the United States. Am J Public Health. 1988;78: 1422-1427.
2. Brown MS, Goldstein JL. Heart attacks: gone with the century? Science. 1996;272:629.
3. US Public Health Service, National Center for Health Statistics. Vital Statistics of the United States. Washington DC: US Government Printing Office; 1988.
4. Dhawan J. Coronary heart disease in Asian Indians. Curr Opin Lipidol. 1996;7:196-198.
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. National Cholesterol Education Program: second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 1994;89: 1329-1445.
6. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease. 7th ed. New York, NY: McGraw-Hill Book Co; 1995:1981-2030.
7. Byington RP, Jukema JW, Salonen JT, et al. Reduction in cardiovascular events during pravastatin therapy: pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation. 1995;92:2419-2425.
8. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;334:1383-1389.
9. Sacks FM, Pfeffer MA, Moye LA, et al, for the Cholesterol and Recurrent Events Trial Investigators. The effects of pravastatin in coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996; 335:1001-1003.
10. Shepherd J, Cobbe SM, Ford I, et al, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;33:1301-1307.
11. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986;232:34-47.
12. Grundy SM, Denke MA. Dietary influences on serum lipids and lipoproteins. J Lipid Res. 1990; 31:1149-1172.
13. Daumeri CM, Woollett LA, Dietary JM. Fatty acids regulate hepatic low density lipoprotein receptor activity through redistribution of intracellular cholesterol pools. Proc Natl Acad Sci U S A. 1992;89:10797-10801.
14. Dietschy JM, Turley SD, Spady DK. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostatisis in different animal species, including humans. J Lipid Res. 1993; 34:1637-1660.
15. Endo A. The discovery and development of HMG CoA reductase inhibitors. J Lipid Res. 1992;33: 1569-1582.
16. Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med. 1988;319:24-33.
17. Endo A, Kuroda M, Tanzawa K. Competitive inhibition of 3-hydroxy-3-methyglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett. 1976;72:323-326.
18. Bilheimer DW, Grundy SM, Brown MS, Goldstein JL. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci USA. 1983;80:4124-4128.
19. National Cholesterol Education Program Expert Panel. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med. 1988;148:36-69.
20. Kannel WB. Contributions of the Framingham Study to the conquest of artery disease. Am J Cardiol. 1988;62:1109-1112.
21. Smith SC, Blair SN, Criqui MH, et al, for the Secondary Prevention Panel. Preventing heart attack and death in patients with coronary disease. Circulation. 1995;92:2-4.
22. Fuster V, Pearson TA. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. J Am Coll Cardiol. 1996;27:957-1047.
23. Oates JA, Heim CR. Smoking. In: Willerson JT, Cohn JN, eds. Cardiovascular Medicine. New York, NY: Churchill Livingstone Inc; 1995:1829-1834.
24. Davender JB, Rogers WJ, Fisher LD, et al. Effects of smoking on survival and morbidity in patients randomized to medical or surgical therapy in the Coronary Artery Surgery Study (CASS): 10-year follow-up. J Am Coll Cardiol. 1992;20:287-294.
25. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med. 1997;336:1153-1162.
26. Bakker-Arkema RG, Davidson MH, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA. 1996;275:128-133.
27. Locker PK, Jungblurh GL, Francom SF, Hughes GS Jr. Lifibrol: a novel lipid-lowering drug for the therapy of hypercholesterolemia. Clin Pharmacol Ther. 1995;57:73-88.
28. Yokoyama C, Wang X, Briggs MR, et al. SREBP-1, a basic helix-loop-helix-leucine zipper protein that controls transcription of low density lipoprotein receptor gene. Cell. 1993;75:187-197.
29. Gordon DA, Jamil H, Gregg RE, Olofsson S-O, Boren J. Inhibition of the microsomal triglyceride transfer protein blocks the first step of apolipoprotein B lipoprotein assembly but not the addition of bulk core lipids in the second step. J Biol Chem. 1996;271:33047-33053.
30. Haghpassand M, Wilder D, Moberly JB. Inhibition of apolipoprotein B and triglyceride secretion in human hepatoma cells (HepG2). J Lipid Res. 1996;37:1468-1480.
31. Boston AG, Cupples LA, Jenner JL, et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. JAMA. 1996;276:544-548.
32. Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease, evaluated by angiography and clinical events. Circulation. 1993;88:2762-2770.
33. Havel RJ. Triglyceride-rich lipoproteins and atherosclerosis: new perspectives. Am J Clin Nutr. 1994;59:795-799.
34. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb. 1991;11:2-14.
35. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213-219.
36. Plump AS, Smith JD, Hayek T, et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 1992;71:343-353.
37. Zhazng SH, Reddick RL, Piedrahita JA. Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 1992;258:468-471.
38. Miller NE, Thelle DS, Forde OH, Mjos OD. The Tromso Heart Study: high density lipoprotein and coronary heart disease: a prospective case-control study. Lancet. 1977;1:965-968.
39. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a prospective factor against coronary heart disease: the Framingham Study. Am J Med. 1977;62:707-714.
40. Assman G, Schulte H, Oberwittler W, Hause WH. New aspects in the prediction of coronary artery disease: the Prospective Cardiovascular Munster Study. In: Fidge NH, Nestel PJ, eds. Atherosclerosis VII. Amsterdam, the Netherlands: Elsevier Science Publishers; 1986:19-24.
41. Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A. 1994;91:9607-9621.
42. Paszty C, Maeda N, Verstuft J, Rubin EM. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Nutr. 1994;94:899-903.
43. Constantinides P. Plaque hemorrhages, their genesis and their role in supraplaque thrombosis and atherogenesis. In: Glagov S. Newman WP, Schaffer SA, eds. Pathology of the Human Atherosclerotic Plaque. New York, NY: Springer-Verlag NY Inc; 1990:393-411.
44. Davis MJ. A macro and micro view of coronary vascular insult in ischemic heart disease. Circulation. 1990;82(suppl II):II-38-II-46.
45. Brown BG, Zhoa X-Q, Sacco DE, Albers JJ. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 1993;87:1781-1791.
46. Libby P. Molecular basis of the acute coronary syndromes. Circulation. 1995;91:2844-2850.
47. Steinberg D, Witztum JL. Lipoproteins and atherogenesis: current concepts. JAMA. 1990;264: 3047-3052.
48. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes: implications for plaque rupture. Circulation. 1994;90:775-778.
49. National Heart, Lung, and Blood Institute. National Heart, Lung, and Blood Institute cholesterol awareness surveys, 1995. Presented at a press conference of the National Heart, Lung, and Blood Institute; December 4, 1995: Bethesda, Md.
50. Kuller L, Borhani N, Furberg C, et al. Prevalence of subclinical atherosclerosis and cardiovascular disease and association with risk factors in the cardiovascular health study. Am J Epidemiol. 1994;139:1164-1179.
51. Arad Y, Spadara LA, Goodman K, et al. Predictive value of electron beam computed tomography of the coronary arteries: 19-month follow-up of 1173 asymptomatic subjects. Circulation. 1996;93:1951-1953.
52. National Diabetes Data Group. Diabetes in America. 2nd ed. Bethesda, Md: National Institute of Diabetes and Digestive and Kidney Disorders; 1995. National Institutes of Health publication 95-1468.
53. Pyorala K, Pedersen TR, Kjekshus J. The effect of cholesterol lowering with simvastatin on coronary events in diabetic patients with coronary heart disease. Diabetes. 1995;44(suppl 1):35A. Ab-stract 125.
54. Denke MA, Grundy SM. Hypercholesterolemia in the elderly: resolving the treatment dilemma. Ann Intern Med. 1990;112:780-792.
55. Centers for Disease Control and Prevention. Daily dietary fat and total food energy intakes: Third National Health and Nutrition Examination Survey, Phase I. MMWR Morb Mortal Wkly Rep. 1994;43:116-125.
56. Johnson CL, Rifkind BM, Sempos CT, et al. Declining serum cholesterol levels among US adults: the National Health and Nutrition Examination surveys. JAMA. 1993;269:3002-3008.
57. Law MR, Wald NJ, Wu T, Hackshaw A, Bailey A. Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study. BMJ. 1994;308:363-366.
58. Law MR, Wald NJ, Thompson SM. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ. 1994;308:367-373.
59. Denke MA. Cholesterol-lowering diets: a review of the evidence. Arch Intern Med. 1995;155:17-26.
60. Finnegan LP. The NIH Women's Initiative: its evolution and expected contributions to women's health. Am J Prev Med. 1996;12:292-293.
61. Nutrition and Your Health: Dietary Guidelines for Americans. Washington, DC: US Dept of Agriculture; 1990. US Dept of Health and Human Services Home and Garden bulletin 232.
62. Kang SS, Wong PW, Noroosis M. Homocysteinemia due to folate deficiency. Metabolism. 1987; 36:458-462.
63. Kang SS, Wong PW, Malinow MR. Hyperhomocysteinemia as a risk factor for occlusive vascular disease. Ann Rev Nutr. 1992;12:279-298.
64. Thomas PR, Earl R, eds. Opportunities in the Nutrition and Food Sciences: Research Challenges and the Next Generation of Investigators. Washington, DC: National Academy Press; 1994.
65. PDAY Research Group. Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking: a preliminary report from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. JAMA. 1990;264:3018-3024.
66. McGill HC Jr, McMahan CA, Malcom GT, Oalmann MC, Strong JP, for the PDAY Research Group. Effects of serum lipoproteins and smoking on atherosclerosis in young men and women. Arterioscler Thromb Vasc Biol. 1997;17:95-107.
67. US Dept of Health and Human Services. Physical Activity and Health: A Report of the Surgeon General. Atlanta, Ga: US Dept of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion; 1996.
68. Grundy SM. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation. 1997;95:1-4.
69. Reaven GM. Insulin resistance and compensatory hyperinsulinemia: role in hypertension, dyslipidemia, and coronary heart disase. Am Heart J. 1991;121:1283-1288.
70. Guyer MS, Collins FS. How is the Human Genome Project doing, and what have we learned so far? Proc Natl Acad Sd U S A. 1995;92: 10841-10848.